Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6158262 | American Journal of Kidney Diseases | 2010 | 12 Pages |
Abstract
Using ESAs to target a hemoglobin level >12 g/dL is associated with worse clinical outcomes and significant additional cost compared with using ESAs to target lower hemoglobin levels (9-12 g/dL). Given a lack of studies comparing low (9-10.9 g/dL) and intermediate (11-12 g/dL) hemoglobin targets for clinical outcomes, including quality of life, the most cost-effective hemoglobin level target within the range of 9-12 g/dL is uncertain, although aiming for higher targets within this range will lead to higher costs.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Fiona M. PhD, Scott MD, MSc, Marcello MD, SM, Natasha MMath, PStat, Brenda MD, PhD, Braden J. MD, MSc,